BREAKING: Brazil’s Pharma Trademark Boom – AI, CBD, and High-Stakes IP Wars
Key insights from INPI RPI2825 data (Feb 2025):
Why This Matters for Pharma & IP Leaders:
✅ AI-Driven Drug Development: 28% of Class 5 (Pharma) filings now integrate AI (e.g., HIY.AI
Healthcare).
✅ CBD Dominance: Montjuic S.A. leads with Erb CBD Pharma Grade (+34% YoY growth!).
High-Risk Zones: 320+ oppositions in Class 5 – generic vs. branded drug wars escalate.
Untapped Opportunities: Psychedelics & telemedicine trademarks remain wide open.
Act Now or Lose Ground:
1️⃣ Secure hybrid trademarks (Class 5 + 42 for AI-pharma tools).
2️⃣ Partner with CBD innovators before markets saturate.
3️⃣ Avoid São Paulo’s opposition battlegrounds – use predictive tools like TWS IP AI.
Free Risk Assessment:
Comment “PHARMA IP” or DM me for a custom trademark audit.
Want the Full 15-Page Report?
Comment “REPORT” below – I’ll send it FREE to your inbox.
Tag Your Team:
IP Attorneys | Pharma Execs | Investors
Data doesn’t lie – but your competitors won’t wait.
hashtag
hashtagPharmaTrends hashtag
hashtagTrademarkStrategy hashtag
hashtagAIInHealthcare hashtag
hashtagCBD hashtag
hashtagBrazilIP
M. J. Zanon
Brazilian IP Attorney | Pharma IP Strategist
[email protected] | www.mjzanon.com